Adragos Hub

Outsourcing commercial manufacturing is never only a capacity decision. For creams, gels, ointments and non-sterile liquids, it is a quality, supply continuity and patient safety decision. A sponsor can transfer a formula, a method and a target batch size. What […]

Selecting a CDMO for high-potency active pharmaceutical ingredient development requires more than checking whether a partner “handles HPAPIs”. Pharma and biotech teams need to understand whether the CDMO can combine formulation expertise, proven containment, analytical development, GMP manufacturing, cleaning validation […]

Adragos Pharma is pleased to announce its participation in Biotech Outsourcing Strategies (BOS) Basel 2026, taking place in Basel, Switzerland, from June 30 to July 1. As a global Contract Development and Manufacturing Organisation (CDMO), we look forward to connecting […]

Selecting a Contract Development and Manufacturing Organisation (CDMO) for high-potency active pharmaceutical ingredient (HPAPI) small molecule formulation development requires a verification process that is fundamentally more rigorous than for standard compound programmes. The containment infrastructure, operator safety controls and Good […]

Adragos Pharma provides sterile injectable fill-finish Contract Development and Manufacturing Organisation (CDMO) services across three European manufacturing sites in France and Switzerland, supported by visual inspection and packaging capability in Japan. From early-phase clinical batches through to high-volume commercial supply, […]

To evaluate a Contract Development and Manufacturing Organisation (CDMO) for Occupational Exposure Band 5 (OEB5) High Potency Active Pharmaceutical Ingredient (HPAPI) small molecule formulation, Chemistry, Manufacturing and Controls (CMC) and procurement teams should apply a five-domain weighted scorecard across written […]